Children’s Hospital Medical Center, Cincinnati – Neuroblastoma

Access Program Information

<p>Currently there is no known effective treatment for patients with advanced stage <strong>neuroblastoma, pheochromocytoma, or paraganglioma</strong> who have relapsed or not responded to standard therapy. In previous studies that used 131I-MIBG as a potential anti-cancer therapy, a decrease in the size of tumors was seen in some of the children and adults.</p>
<p>This research study will continue to evaluate the side effects of 131I-MIBG when treating children and adults with <strong>neuroblastoma, pheochromocytoma, or paraganglioma.</strong> The 131I-MIBG compound is intended to work by selectively delivering the radioactive iodine to the tumor cells, which is then intended to result in their destruction. The purpose of this research study is to: – Make 131I-MIBG therapy available to patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma – Further assess the side effects of 131I-MIBG therapy</p>

Rare Disease: